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Abstract
Purpose: To investigate the prognostic value of survivin expression in pretreatment specimens from patients with
anal cancer treated with concurrent 5-FU and mitomycin C-based chemoradiation (CRT).
Material and methods: Immunohistochemical staining for survivin was performed in pretreatment biopsies of 62
patients with anal carcinoma. Survivin expression was correlated with clinical and histopathological characteristics
as well as local failure free- (LFFS), distant metastases free- (DMFS), cancer specific- (CSS), and overall survival (OS).
Results: Survivin staining intensity was weak in 10%, intermediate in 48% and intense in 42% of the patients. No
association between survivin expression and clinicopathologic factors (tumor stage, age and HIV status) could be
shown. In univariate analysis, the level of survivin staining was significantly correlated with DMFS (low survivin vs.
high survivin: 94% vs. 74%, p=0.04). T-stage, N-stage and the tumor grading were significantly associated with OS
and CSS and with DMFS and LFFS, respectively. In multivariate analysis, survivin was confirmed as independent
prognostic parameter for DMFS (RR, 0.04; p=0.02) and for OS (RR, 0.27; p=0.04).
Conclusion: Our results demonstrated that the level of pretreatment survivin is correlated with the clinical
outcome in patients with anal carcinoma treated with concurrent CRT. Further studies are warranted to elucidate
the complex role of survivin for the oncologic treatment and to exploit the protein as a therapeutic target in
combined modality treatment of anal cancer.
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Background
Survivin, the smallest and structurally unique member
of the inhibitor of apoptosis protein family (IAP) [1]
plays a prominent role within tumor biology [2]. As a
prime example of a nodal cancer protein, it is involved
in the regulation of a multitude of cellular networks, in-
cluding tumor cell proliferation, apoptosis and response
to unfavorable environmental conditions [3]. While it is
highly expressed during fetal development and is down
regulated in most terminally differentiated normal
tissues, the protein is found to be re-expressed in virtu-
ally every human malignancy examined so far [4,5]. In
line with that, survivin has been recognized as a suitable
prognostic and predictive marker for tumor onset,
enhanced proliferative index, more aggressive tumor
behavior and strongly correlates with a higher likelihood
of tumor recurrence and impaired disease free- and
overall survival rates [4,6]. Moreover, a correlation of
elevated survivin expression with increased risk of recur-
rences, lymph node metastases, and shorter survival was
shown beside others, in non-small cell lung cancer
(NSCLC), T1 bladder carcinoma [7], rectal adenocarcin-
oma [8] and locally advanced prostate cancer [9] treated
with radiation therapy or chemoradiation. Due to its
universal over-expression and unique biological proper-
ties, survivin further displays a validated molecular
target for cancer drug development [10,11]. A variety of
preclinical studies have demonstrated that targeting the
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mutants, antisense oligonucleotides and small molecule
repressors sensitized tumor cells towards chemotherapy
and irradiation and reduced tumor growth potential
[6,12]. In addition, the translation of the preclinical
findings into clinical practice is currently under way as a
variety of survivin antagonists entered clinical phase I/II
trials [13,14].
In anal cancer, the prognostic value of apoptosis asso-
ciated proteins has only been evaluated in a few studies
on a restricted number of patients [15-19] showing that
expression of Bcl-2, M30, p53, and nuclear factor κB
(NF-κB) may be an independent predictor for disease
free survival (DFS) and local control (LC), respectively.
By contrast, a prognostic or predictive impact of survivin
expression has not yet been investigated. Thus, the ob-
jective of the present study was to evaluate the expres-
sion of survivin in pretreatment biopsy specimen of
patients with anal carcinoma treated with concurrent
CRT and to correlate its immunoreactive score with clin-
icopathologic characteristics and clinical outcome.
Patients and methods
Patients
62 patients, uniformly treated with definitive CRT for
anal cancer in the Department of Radiotherapy and On-
cology of the University Hospital of Frankfurt am Main
and at the Department of Radiation Therapy of the Uni-
versity Hospital of Erlangen, who had available biopsy
tissues and provided informed consent, were included in
this study. Eligibility criteria were histological proof of
anal canal carcinoma (squamous cell or basaloid or cloa-
cogenic subtype) and curative intent of 5-FU and Mito-
mycin C-based CRT. Pretreatment evaluation consisted
of physical and rectal-digital examination, proctoscopy
with biopsy, CT/MRI of the abdomen and pelvis, chest
x-ray, serum chemistry, and complete blood count in all
patients. Patients were staged according to the system
adopted by the Union International Contre le Cancer
(UICC) and the American Joint Committee on Cancer.
Treatment modalities and follow-up
3-D conformal radiation therapy was performed using
either a 6- or 25-MV photon beam linear accelerator
with individual field arrangement. The target volume
included the primary tumor and the mesorectal, inguinal
and internal iliac lymph nodes. The patients were treated
with a median dose of 50.4 Gy (range, 41.4–60 Gy) with
daily fractions of 1.8–2 Gy. A brachytherapy-boost with
a median dose of 14 Gy (range, 12–22 Gy) was applied
in 4 patients. 27 patients received an external boost to
the primary tumor and/or enlarged lymph nodes of
5.4 Gy (range, 1.8–10.8 Gy). The anal boost volume was
defined as anal gross tumor plus a safety margin of 2 cm
in each direction. The dose specification was based on
ICRU Report 50 recommendations. Concurrent chemo-
therapy consisted of two cycles of 5-FU (1.000 mg/m
2/
24 hours) as 4 or 5-day continuous infusion in the first
and fifth week of radiotherapy; mitomycin C was admi-
nistered as intravenous bolus on day one of each cycle.
During the treatment, patients were evaluated weekly to
assess acute toxicity and compliance with the chemora-
diation. Initial treatment response was assessed by
rectal-digital examination and proctoscopy, with biopsies
taken in case of suspicious residual tumor, 6–8 weeks
after completion of CRT. The lymph node status was
documented by pelvic CT/MRI-scan. Patients were
scheduled for follow-up examinations, including history,
physical and rectal-digital examination, and proctoscopy
with biopsy in case of any suspicious finding, every
3 months for 2 years, followed every 6 months subse-
quently. Local control was defined as control of the anal
primary tumor while nodal failure was considered as
locoregional relapse. The median follow up time was
68 months (range 9–246).
Immunohistochemical detection of survivin
Immunohistochemical staining of survivin was per-
formed on anal cancer biopsies by a horseradish-
peroxidase technique using a DAKO Autostainer plus
(DAKO, Hamburg, Germany) according to the manufac-
turer’s recommendation. For staining purpose, paraffin
embedded tissue either mounted on microscope slides
(Star Frost, Engelbrecht, Germany) or tissue microarrays
as described in [20] were pretreated for 20 min with an
Epitope Retrieval Solution (Dako). Next, slides were sub-
jected to an automatic staining procedure with standar-
dized H202 (10%) treatment (10 min) and antibody
(AF886, R&D Systems, Wiesbaden, Germany) incubation
(20 min, 1:750). Next, dextran polymer conjugated
horseradish-peroxidase and 3,3’-diaminobenzidine (DAB)
chromogen was used for visualization of the epitope-
antibody reaction product and hematoxylin (37%) for
counterstaining. Negative control slides in the abcense of
primary antibodies and positive controls with formalin-
fixed, paraffin-embedded cancer specimens of known sur-
vivin reactivity were included for each staining.
Scoring of survivin expression
Survivin immunoreactivity was analyzed considering
both the percentage of positive cells and the intensity of
staining. The staining intensity was scored as: 1+ (weak),
2+ (moderate) and 3+ (intense). The fraction of tumor
cells with survivin positivity was assigned to: 1 (0–25%),
2 (26–50%), 3 (51–75%) and 4 (> 75%). To minimize
interobserver variability, scoring was performed by two
independent investigators without knowledge of the clin-
icopathological data. In discrepant cases, a final decision
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if necessary, a recount of the labeled cells was done. The
percentage of positive tumor cells and the staining inten-
sity were then multiplied to produce an individual label-
ing score for each case, ranging from 0 (no positive
tumor cells) to 12 (> 75% of tumor cells with intense
staining). A weighted score≤8 was defined as “low” sur-
vivin expression and a weighted score of>8a s“high”
survivin expression. This dichotomous variable served
for correlation of survivin expression with clinicopatho-
logical parameters and survival.
Statistical analysis
Mean values are indicated with standard deviation. Differ-
ences between groups on continuous variables were tested
using the Mann–Whitney test. Fisher’s exact test was used
to test differences between groups on categorical variables.
Survival and time to recurrence were calculated from the
date of CRT-beginning to the day of death and recur-
rences, respectively, or the date of the last follow-up. Dis-
ease free survival (DFS) was defined as the time between
the start of CRT and tumor relapse (locoregional recur-
rence and/or distant metastases) or death due to non-
tumor related causes. Local failure free survival (LFFS)
was defined as the time from the start of CRT to the first
local tumor detection after CRT (i.e. non-complete re-
sponse), local tumor recurrence after complete response
or death from any cause. Survival curves were plotted
according to the Kaplan-Meier method using SPSS 15.0
for Windows. Survival comparison between groups used
the log-rank (Mantel-Cox) test.
The multivariate analysis was carried out with the Cox
proportional hazard models.
Results
Survivin immunostaining on pretreatment biopsies
The intensity of survivin staining was usually homogeneous
within a tumor specimen tested, but varied considerably
among individual tumors. In Figure 1, representative exam-
ples of intense (>75 positive tumor cells), intermediate
(25–75%) and weak (≤ 25%) survivin immunoreactivity are
illustrated. The distribution of the staining characteristics
and labeling scores is presented in Table 1. As a dichotom-
ous variable, survivin expression was defined as “low”
(weighted score≤8) in 36 patients (58%) and “high”
(weighted score>8) in 26 patients (42%). As shown in
Table 2, no significant relationship was found for the
dichotomized variable and clinicopathologic parameters
such as T-stage, N-stage, age and HIVstatus.
Survivin and treatment response
After CRT, a clinical complete response was diagnosed
in 55 patients (low survivin vs. high survivin: 89% vs.
88%, p=1.0). Within these patients, a local recurrence
occurred in 6 patients (16% vs. 4%, p=0.38). Local con-
trol was achieved in 49 patients (75% vs. 86%, p=0.53).
Distant metastases were evident in 8 patients (6% vs.
23%, p=0.05). Within the 15 patients who have died
(19% vs. 31%, p=0.37), 9 patients died from anal cancer
(12% vs. 26%, p=0.47), two patients died from intercur-
rent disease and 4 patients from unknown causes.
As displayed in Figure 2, patients with low survivin ex-
pression had a significantly superior DMFS (94% vs.
74%, p=0.04). OS was also superior, but without signifi-
cance (92% vs. 75%, p=0.09). In univariate analysis, the
T-stage, N-stage and the tumor grading were also signifi-
cantly associated with OS and CSS and with DMFS and
LFFS, respectively (Table 3). Factors significantly influen-
cing the clinical endpoints such as survivin expression,
T-stage, N-stage and tumor grading as well as patients’
gender were included in multivariate analysis. In the
Cox models, survivin was confirmed as an independent
prognostic parameter for DMFS (RR, 0.04; p=0.02) and
for OS (RR, 0.27; p=0.04). As depicted in Table 4, T-
stage was also an independent prognostic factors for
DMFS (RR, 1.88; p=0.02).
Discussion
Despite respectable treatment response in non-
metastatic anal carcinoma with OS rates of 60–75%, only
a small amount of patients (10%) with distant metastases
will survive more than two years from the time of diag-
nosis [21]. Although clinical and pathological factors like
tumor size and extent and nodal involvement have been
regarded to be of prognostic significance, biomarkers
have not yet been consistently be proven to predict
tumor response [22]. Whereas some studies reported on
a prognostic value of TP53, p21 and cyclin A, other
investigations did not [23]. Thus, extended insights into
individual tumor characteristics and the development of
novel molecular indicators are seriously needed.
Deregulation of apoptosis is a pathogenic factor of
many human diseases, and the ability to circumvent or
evade apoptotic cell death is a critical hallmark of tumor
cells [24]. Since deregulation in cell death pathways, for
example by an elevated expression of anti-apoptotic
molecules, may result in resistance to conventional treat-
ment regimens including chemo and radiation therapy,
these markers may be a novel class of molecular predic-
tors. In the present study, we investigated the predictive
and prognostic relevance of the apoptosis inhibitor sur-
vivin in biopsies derived from patients with anal carcin-
oma treated with definitive CRT. By using histochemical
evaluation and scoring we demonstrated that pretreat-
ment survivin expression is correlated with the clinical
outcome-namely DMFS. These findings are in line with
a variety of studies showing that a high survivin expres-
sion is correlated with increased risk of tumor
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after definitive radiotherapy or chemoradiation in
esophageal [25], cervical [26], lung [27], early (T1/T2)
prostate [9], and in nasal/paranasal sinus cancer [28].
More recent data further indicate that intratumoral sur-
vivin expression significantly decreased during neoadju-
vant chemoradiation in esophageal and rectal cancer
[29,30]. A failure in radiation provoked down-regulation,
by contrast, was significantly associated with shortened
overall survival and an increased likelihood to develop
distant metastases. These results support the concept
that measuring survivin expression may be suitable to
predict individual metastatic behavior. To strengthen
this hypothesis, an intermolecular cooperation between
survivin and its family partner X-linked IAP (XIAP) has
recently been reported to stimulate an invasive behavior
and promote tumor cell metastases. Thus, both proteins
are considered to modulate metastasis progression, pos-
sibly orchestrating a cellular network of transcription
factor NF-κB dependent expression of fibronectin, β-
integrin signaling and activation of the cell motility
kinases focal adhesion molecule (FAK) or matrix metal-
loproteinases [31,32].
a b c
Figure 1 Examples of anal cancer biopsies with intense (a), intermediate (b) and weak (c) immunohistochemical staining of survivin in
both, cytoplasm and nucleus of tumor cells. Original magnification x 100 (a,b,c) and x 400 (inserts), scale bar: 100 μm.
Table 1 Results of immunohistochemistry
Patients
n (%)
Percentage of immunopositive cells:
0–25% 1 (2)
26–50% 6 (10)
51–75% 10 (16)
76–100% 45 (72)
Staining intensity:
1+ 6 (10)
2+ 30 (48)
3+ 26 (42)
Individual labeling score:
1–3 6 (10)
4–8 30 (48)
9–12 26 (42)
Dichotomized labeling score:
≤ 8 36 (58)
>8 26 (42)
Table 2 Patients characteristics
No. of
patients
low survivin* high survivin** p-value
n (%) n (%)
Age
≤ 56 years 31 19 (53) 12 (46) 0.79
> 56 years 31 17 (47) 14 (54)
Sex
Male 26 15 (42) 11 (42) 1.0
Female 36 21 (58) 15 (58)
HIV-status
Positive 15 7 (19) 8 (31) 0.37
Negative 47 29 (81) 18 (69)
T-stage
T1/2 44 26 (72) 18 (62) 0.78
T3/4 17 9 (25) 8 (31)
Tx 1 1 (3) 0 (0)
N-stage
N0 37 18 (50) 19 (73) 0.18
N+ 23 16 (44) 7 (27)
Nx 2 2 (6) 0 (0)
Grading
G1/2 47 27 (75) 20 (77) 0.75
G3 12 6 (17) 6 (23)
Gx 3 3 (8) (0)
Abbreviations: HIV=human immunodeficiency virus.
*survivin - weighted score≤8; **survivin - weighted score>8.
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normal tissue and its requirement for regulating apop-
tosis, maintaining cancer cell viability and to modulate
therapy response, survivin is supposed to be a suitable
target for a molecular tumor therapy [10,11]. Indeed a
variety of preclinical studies have convincingly demon-
strated that survivin is a radiation resistance factor
[33-35]. Moreover, attenuation of the protein by anti-
sense oligonucleotides (ASO), small interfering RNAs
(siRNAs), small molecule transcriptional inhibitors and
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Figure 2 Distant metastases free survival (DMFS) (a) and Overall survival (OS) (b) according to pretreatment survivin expression (low
survivin: weighted score≤8; high survivin: weighted score>8).
Table 3 Univariate analysis for prognostic factors influencing 5 year-survival
OS p-value CSS p-value DMFS p-value LFFS p-value
(%) (%) (%) (%)
Age
≤ 56 years 84 0.17 84 0.75 83 0.47 81 0.46
> 56 years 87 92 88 82
Sex
Male 75 0.41 80 0.30 80 0.20 72 0.08
Female 93 93 89 89
HIV-status
Positive 73 0.27 73 0.07 72 0.08 73 0.13
Negative 90 93 90 84
T-stage
T1/2 93 0.01 93 <0.01 90 0.02 88 0.02
T3/4 67 76 72 64
N-stage
N0 93 <0.01 93 <0.01 90 0.19 100 <0.01
N+ 73 78 81 55
Grading
G1/2 91 <0.01 94 0.04 91 0.08 84 0.14
G3 64 64 65 75
Survivin
low* 92 0.09 92 0.29 94 0.04 80 0.56
high** 75 82 74 85
Abbreviations: OS=overall survival; CSS=cancer specific survival; DMFS=distant metastases-free survival; LFFS=local failure-free survival; HIV=human
immunodeficiency virus. *Survivin - weighted score≤8; **survivin - weighted score>8.
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survival, radiosensitized glioblastoma [33], colorectal
carcinoma [36], non-small cell lung cancer cells [37],
and reduced tumor growth in xenograft models [6,12].
The translation of these preclinical findings to the clin-
ical practice is currently under way with a number of
phase I/II trials targeting survivin by the use of ASO
(LY2181308) and small molecule inhibitors (YM155) in
progress [13,14]. However, first results indicate modest
activity as single agents [38,39], but it is anticipated that
when given combined with conventional chemothera-
peutic drugs or irradiation these agents may exhibit
enhanced individual success. Thus it is tempting to
speculate, that combined anti survivin and CRT therapy
in anal carcinoma will emerge as a novel treatment op-
tion in patients overexpressing the protein.
To the best of our knowledge, this is the first report
evaluating survivin expression in anal carcinoma undergo-
ing definitive CRT based on a well documented patient
cohort and tumor material available. Although our investi-
gation has some limitations due to restricted number of
patients, low statistical power, and potential cut-point bias
we consider the results as representative for a larger group
of patients. Nevertheless, a prospective validation of the
impact of survivin expression in anal carcinoma has to be
performed on the basis of a clinical trial including a stan-
dardized protocol of immunohistochemical evaluation of
the protein in pretreatment specimens.
In conclusion, we have shown that a histochemical
evaluation of survivin expression in pretreatment biop-
sies of patients with anal carcinoma provides an easy ac-
cessible molecular indicator to identify patients at risk of
distant metastatic disease. Based on these results,
patients with high baseline survivin levels might benefit
from intensified chemotherapeutic regimes and may be
selected for additional molecular targeted strategies in
future clinical trials.
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